Ke T, Chang S, Yeh C, Lin S, Yeh K
Sci Rep. 2025; 15(1):5659.
PMID: 39955350
PMC: 11829992.
DOI: 10.1038/s41598-025-90025-z.
Sabit H, Arneth B, Abdel-Ghany S, Madyan E, Ghaleb A, Selvaraj P
Cells. 2024; 13(19).
PMID: 39404428
PMC: 11475877.
DOI: 10.3390/cells13191666.
Shapaer T, Chen Y, Pan Y, Wu Z, Tang T, Zhao Z
Discov Oncol. 2024; 15(1):446.
PMID: 39276259
PMC: 11401830.
DOI: 10.1007/s12672-024-01321-5.
Seifi Z, Khazaei M, Cheraghali D, Rezakhani L
Heliyon. 2024; 10(11):e31589.
PMID: 38845895
PMC: 11153114.
DOI: 10.1016/j.heliyon.2024.e31589.
Sengupta A, Singh S, Kumar R
ACS Omega. 2024; 9(16):18584-18592.
PMID: 38680332
PMC: 11044175.
DOI: 10.1021/acsomega.4c01195.
Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites.
Iwata M, Haraguchi R, Kitazawa R, Ito C, Ogawa K, Takada Y
J Cell Mol Med. 2024; 28(7):e18193.
PMID: 38506205
PMC: 10952021.
DOI: 10.1111/jcmm.18193.
Expression and prognosis of ADAMTS18 in different tumors.
Guo W, Zhang Y
Front Oncol. 2024; 14:1347633.
PMID: 38482210
PMC: 10933061.
DOI: 10.3389/fonc.2024.1347633.
The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.
Samarzija I
Biomedicines. 2024; 12(1).
PMID: 38255186
PMC: 10813710.
DOI: 10.3390/biomedicines12010079.
Exploring extracellular matrix and prostaglandin pathway alterations across varying resection margin distances of right-sided colonic adenocarcinoma.
Suwatthanarak T, Tanjak P, Suwatthanarak T, Acharayothin O, Thanormjit K, Chaiboonchoe A
BMC Cancer. 2023; 23(1):1202.
PMID: 38062443
PMC: 10702019.
DOI: 10.1186/s12885-023-11595-7.
Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis.
Wu Q, He X, Liu J, Ou C, Li Y, Fu X
Cancer Cell Int. 2023; 23(1):223.
PMID: 37777759
PMC: 10543838.
DOI: 10.1186/s12935-023-03061-y.
Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets.
Shakhpazyan N, Mikhaleva L, Bedzhanyan A, Gioeva Z, Sadykhov N, Mikhalev A
Biomedicines. 2023; 11(9).
PMID: 37760801
PMC: 10525158.
DOI: 10.3390/biomedicines11092361.
Stage-Dependent Levels of Brain-Derived Neurotrophic Factor and Matrix Metalloproteinase 9 in the Prognosis of Colorectal Cancer.
Vecurkovska I, Maslankova J, Tomeckova V, Katuchova J, Kiskova T, Frohlichova L
Biomedicines. 2023; 11(7).
PMID: 37509480
PMC: 10377127.
DOI: 10.3390/biomedicines11071839.
A perfused multi-well bioreactor platform to assess tumor organoid response to a chemotherapeutic gradient.
Wasson E, He W, Ahlquist J, Hynes W, Triplett M, Hinckley A
Front Bioeng Biotechnol. 2023; 11:1193430.
PMID: 37324446
PMC: 10264793.
DOI: 10.3389/fbioe.2023.1193430.
Development and validation of a collagen signature to predict the prognosis of patients with stage II/III colorectal cancer.
Dong S, Wang H, Ji H, Hu Y, Zhao S, Yan B
iScience. 2023; 26(5):106746.
PMID: 37216096
PMC: 10192940.
DOI: 10.1016/j.isci.2023.106746.
TGF-β Pathways Stratify Colorectal Cancer into Two Subtypes with Distinct Cartilage Oligomeric Matrix Protein (COMP) Expression-Related Characteristics.
Ding J, Zhou H, Huang Y, Peng J, Huang H, Yi H
Biomolecules. 2022; 12(12).
PMID: 36551305
PMC: 9775768.
DOI: 10.3390/biom12121877.
Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer.
Li H, Zeng C, Shu C, Cao Y, Shao W, Zhang M
Cell Death Dis. 2022; 13(12):1028.
PMID: 36477408
PMC: 9729302.
DOI: 10.1038/s41419-022-05472-7.
mRNAsi-related metabolic risk score model identifies poor prognosis, immunoevasive contexture, and low chemotherapy response in colorectal cancer patients through machine learning.
Weng M, Li T, Zhao J, Guo M, Zhao W, Gu W
Front Immunol. 2022; 13:950782.
PMID: 36081499
PMC: 9445443.
DOI: 10.3389/fimmu.2022.950782.
Type IV Collagen in Human Colorectal Liver Metastases-Cellular Origin and a Circulating Biomarker.
Lindgren M, Rask G, Jonsson J, Berglund A, Lundin C, Jonsson P
Cancers (Basel). 2022; 14(14).
PMID: 35884455
PMC: 9325127.
DOI: 10.3390/cancers14143396.
Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.
Gupta K, Jones J, de Araujo Farias V, Mackeyev Y, Singh P, Quinones-Hinojosa A
Front Oncol. 2022; 12:840241.
PMID: 35664781
PMC: 9158132.
DOI: 10.3389/fonc.2022.840241.
Immune-and Metabolism-Associated Molecular Classification of Ovarian Cancer.
Chen Z, Jiang W, Li Z, Zong Y, Deng G
Front Oncol. 2022; 12:877369.
PMID: 35646692
PMC: 9133421.
DOI: 10.3389/fonc.2022.877369.